NCT04570839: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. |
|
|
| Completed | 1/2 | 48 | US | COM701 in combination with BMS-986207 and nivolumab. | Compugen Ltd, Bristol-Myers Squibb | Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer | 05/24 | 05/24 | | |
NCT03667716: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. |
|
|
| Completed | 1 | 121 | US | COM701, COM701 with Opdivo (Nivolumab). | Compugen Ltd, Bristol-Myers Squibb | Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Ovarian Neoplasm, Triple Negative Breast Cancer, Lung Neoplasm, Neoplasm Malignant, Colo-rectal Cancer | 01/24 | 01/24 | | |
| Recruiting | 1 | 110 | US | Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab. | Compugen Ltd | Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC | 12/24 | 03/25 | | |
